Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Seeks EU Accelerated Review For CAR-T Therapy

Executive Summary

Novartis, having now submitted its CAR-T therapy CTL019 to the European Medicines Agency for approval, should learn shortly whether the product will be assessed under the agency’s accelerated procedure.

Advertisement

Related Content

EU Filings For Amgen/UCB’s Evenity, iv Relenza From GSK, And A New PRIME Product
Lilly, Novartis, Jazz and Ionis Take New Products To EMA
APOLLO Success Clears Alnylam For Lift-Off
Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval

Topics

Advertisement
UsernamePublicRestriction

Register

PS121913

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel